HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
Satigrel
structure given in first source
Also Known As:
4-cyano-5,5-bis(4-methoxyphenyl)-4-pentenoic acid; E 5510; E-5510; 4-Pentenoic acid, 4-cyano-5,5-bis(4-methoxyphenyl)-
Networked:
3
relevant articles (
1
outcomes,
1
trials/studies)
Relationship Network
Bio-Agent Context: Research Results
Lipids: 114793
Fatty Acids: 27405
Unsaturated Fatty Acids: 8236
Monounsaturated Fatty Acids: 676
Satigrel: 3
Related Diseases
1.
Intermittent Claudication
12/01/1996 - "
Satigrel improved the cutaneous circulation and symptoms of patients with intermittent claudication.
"
12/01/1996 - "
The present study assessed the effect of oral satigrel on cutaneous circulation in patients with intermittent claudication due to arteriosclerosis obliterans.
"
2.
Arteriosclerosis Obliterans
01/01/1998 - "
Nine patients with arteriosclerosis obliterans receiving grafts were treated with satigrel, and 10 others were enrolled as untreated controls.
"
12/01/1996 - "
The present study assessed the effect of oral satigrel on cutaneous circulation in patients with intermittent claudication due to arteriosclerosis obliterans.
"
3.
Thrombosis (Thrombus)
12/01/1996 - "
Satigrel is a new antiplatelet agent which was previously shown to inhibit platelet aggregation and have an anti-thrombotic effect in various animal thrombosis models.
"
4.
Ischemia
11/01/1990 - "
E-5510, however, showed no ameliorative effect on ischemia-induced myocardial dysfunction, as expressed by the decrease in regional myocardial shortening.(ABSTRACT TRUNCATED AT 250 WORDS)
"
Related Drugs and Biologics
1.
Platelet Aggregation Inhibitors (Antiplatelet Drugs)